| Autor: |
Maria Mariana Barros Melo, da Silveira, Leiliandry de Araújo, Melo, Filipe Maia Ferreira, Gomes, Leonardo José de Cupertino Barreto da Rocha, Andrade, Isabela Paulino, Serur, Isabelle Cecília de Vasconcellos, Piscoya, Raposo Marina, Gueiros, Kleyton, Palmeira do Ó, Raul Emídio, de Lima, Victor Arthur Eulálio, Brasileiro, Luydson Richardson Silva, Vasconcelos, Dário Celestino, Sobral Filho |
| Rok vydání: |
2018 |
| Předmět: |
|
| Zdroj: |
The Application of Clinical Genetics |
| ISSN: |
1178-704X |
| Popis: |
Introduction Warfarin continues to be the most widely used anticoagulant in clinical practice around the world for the prevention of thromboembolic events in patients with atrial fibrillation (AF). The evaluation of the quality of anticoagulation control, estimated by time in therapeutic range (TTR), is accepted as a good method to evaluate the quality of anticoagulation. The variability of TTR can be explained by the presence of variants of the CYP2C9 and VKORC1 genes. Methods This study examined the association between polymorphisms of the CYP2C9 and VKORC1 genes and control of oral anticoagulation, through TTR, in patients with AF. A cross-sectional study was conducted within a cohort follow-up. The study comprised of 317 patients with AF, using warfarin, who were followed up for one year. The genotyping of genes CYP2C9 (rs1057910), (rs1799853) and VKORC1 (rs923231) was performed by PCR in real time, using TaqMan probes. Results Patients who had variant genotypes for the CYP2C9*3 gene (rs1057910) presented higher TTR (TTR 81–100%) when compared to when compared to the |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
